Canada · Delayed Price · Currency is CAD BriaCell Therapeutics Statistics
Total Valuation
TSX:BCT has a market cap or net worth of CAD 42.49 million. The enterprise value is 973,213.
| Market Cap | 42.49M |
| Enterprise Value | 973,213 |
Important Dates
The next estimated earnings date is Friday, June 5, 2026.
| Earnings Date | Jun 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TSX:BCT has 7.25 million shares outstanding. The number of shares has increased by 784.70% in one year.
| Current Share Class | 7.25M |
| Shares Outstanding | 7.25M |
| Shares Change (YoY) | +784.70% |
| Shares Change (QoQ) | +48.75% |
| Owned by Insiders (%) | 2.52% |
| Owned by Institutions (%) | 2.40% |
| Float | 6.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.04 |
| P/TBV Ratio | 1.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.02 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.10
| Current Ratio | 10.10 |
| Quick Ratio | 9.39 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -831.19 |
Financial Efficiency
Return on equity (ROE) is -179.21% and return on invested capital (ROIC) is -114.89%.
| Return on Equity (ROE) | -179.21% |
| Return on Assets (ROA) | -89.44% |
| Return on Invested Capital (ROIC) | -114.89% |
| Return on Capital Employed (ROCE) | -101.08% |
| Weighted Average Cost of Capital (WACC) | 14.17% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -2.51M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.26% in the last 52 weeks. The beta is 1.80, so TSX:BCT's price volatility has been higher than the market average.
| Beta (5Y) | 1.80 |
| 52-Week Price Change | -91.26% |
| 50-Day Moving Average | 5.94 |
| 200-Day Moving Average | 14.79 |
| Relative Strength Index (RSI) | 46.71 |
| Average Volume (20 Days) | 17,135 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -41.69M |
| Pretax Income | -40.64M |
| Net Income | -40.20M |
| EBITDA | -41.55M |
| EBIT | -41.69M |
| Earnings Per Share (EPS) | -27.10 |
Balance Sheet
The company has 40.56 million in cash and n/a in debt, with a net cash position of 40.56 million or 5.59 per share.
| Cash & Cash Equivalents | 40.56M |
| Total Debt | n/a |
| Net Cash | 40.56M |
| Net Cash Per Share | 5.59 |
| Equity (Book Value) | 40.98M |
| Book Value Per Share | 5.78 |
| Working Capital | 39.33M |
Cash Flow
| Operating Cash Flow | -42.00M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 146,512 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSX:BCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -784.70% |
| Shareholder Yield | -784.70% |
| Earnings Yield | -94.62% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 25, 2025. It was a reverse split with a ratio of 0.1.
| Last Split Date | Aug 25, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |